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control in patients with hypertension – a
cross-sectional database study
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Abstract
Background: Patients requiring anticoagulation suffer from comorbidities such as hypertension. On the occasion of
INR monitoring, general practitioners (GPs) have the opportunity to control for blood pressure (BP). We aimed to
evaluate the impact of Vitamin-K Antagonist (VKA) monitoring by GPs on BP control in patients with hypertension.
Methods: We cross-sectionally analyzed the database of the Swiss Family Medicine ICPC Research using Electronic
Medical Records (FIRE) of 60 general practices in a primary care setting in Switzerland. This database includes 113,335
patients who visited their GP between 2009 and 2013. We identified patients with hypertension based on antihypertensive
medication prescribed for ≥6 months. We compared patients with VKA for ≥3 months and patients without such
treatment regarding BP control. We adjusted for age, sex, observation period, number of consultations and comorbidity.
Results: We identified 4,412 patients with hypertension and blood pressure recordings in the FIRE database. Among
these, 569 (12.9 %) were on Phenprocoumon (VKA) and 3,843 (87.1 %) had no anticoagulation. Mean systolic and
diastolic BP was significantly lower in the VKA group (130.6 ± 14.9 vs 139.8 ± 15.8 and 76.6 ± 7.9 vs 81.3 ± 9.3 mm Hg)
(p < 0.001 for both). The difference remained after adjusting for possible confounders. Systolic and diastolic BP were
significantly lower in the VKA group, reaching a mean difference of −8.4 mm Hg (95 % CI −9.8 to −7.0 mm Hg)
and −1.5 mm Hg (95 % CI −2.3 to −0.7 mm Hg), respectively (p < 0.001 for both).
Conclusions: In a large sample of hypertensive patients in Switzerland, VKA treatment was independently
associated with better systolic and diastolic BP control. The observed effect could be due to better compliance
with antihypertensive medication in patients treated with VKA. Therefore, we conclude to be aware of this
possible benefit especially in patients with lower expected compliance and with multimorbidity.
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Background
In times of novel oral anticoagulants (NOACs) coagula-
tion monitoring (International Normalized Ratio testing,
INR) is no longer needed. In several studies, NOACs
have been shown not to be inferior to VKAs in stroke
prevention in patients with atrial fibrillation [1] and in
the treatment of venous thromboembolism [2].
However, there are several reasons why General Practi-
tioners (GPs) may hesitate to switch patients from VKA
to NOAC if INR is in therapeutic range: the higher price
of NOACs, the greater risk of gastrointestinal bleeding
[3], being familiar with perioperative (bridging)-manage-
ment, and lastly no validated strategies for bleeding
complications.
In addition, patients requiring anticoagulation often
suffer from significant co-morbidities such as hyperten-
sion, cardiovascular disease (CVD), diabetes or renal fail-
ure [4]. In many countries, the INR value is monitored
by GPs [5]. On the occasion of INR monitoring, GPs
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have the opportunity to provide additional care to pa-
tients, such as adjusting the dosage of antihypertensive
drugs, giving smoking cessation advice or treating high
cholesterol. Therefore, it could be assumed, that patients
under VKA treatment and consequent INR monitoring
receive more comprehensive care of their comorbidities
than patients without VKA treatment due to a higher
consultation rate. A similar, but possibly confounding ef-
fect has been shown in a large Danish cohort of hyper-
tensive patients, where patients with co-morbidities,
particularly patients with heart failure and CVD had a
significantly better blood pressure (BP) control [6]. This
may indicate that the quality of care increases with the
number of conditions causing a higher consultation rate
and thus closer care management.
In our study, we aimed to evaluate the specific impact
of INR monitoring on BP control in primary care pa-
tients with hypertension. Taking into consideration that
other chronic conditions needing periodical monitoring
could alter observed effects, we also investigated if pa-
tients with comorbid diabetes would differ regarding BP
control. We focused on diabetes for two reasons. First, it
is a chronic disease commonly managed in primary care
with internationally well accepted guidelines uniformly
suggesting a regular recall of patients for the monitoring
of blood sugar target values. Second, it is undisputed
that diabetes itself is an indication for BP control. If INR
monitoring had a specific impact on BP control, it could
be assumed that the effect would also be observed in pa-
tients with comorbid diabetes.
Methods
Primary care patients were identified from the Family
medicine ICPC-Research using Electronic medical re-
cords (FIRE) project database. The FIRE project is an
ongoing research project at the Institute of General
Practice of the University of Zurich, Switzerland. Estab-
lished in 2009, it provides the first and largest standard-
ized collection of structured medical routine data from
Swiss primary care. Details about the database structure
are reported elsewhere [7]. In brief, the database covers
reasons for encounter according to the ICPC-2 classifi-
cation (International Classification of Primary Care 2)
[8], patient demographics, vital signs, laboratory data
and both type and dosage of prescribed medication ac-
cording to Anatomical Therapeutic Chemical/Defined
Daily Dose Classification (ATC/DDD) coding established
by the WHO [9]. General practitioners participating in
the FIRE project extract these data in an anonymized
way from their electronic medical records and pool them
centrally in the FIRE database aggregated by individual
consultation dates.
In our study, we identified patients being treated for
hypertension based on prescribed medication. Cases with
ATC coding specifying antihypertensive medication were
detected following the concept of pharmaceutical cost
groups (PCG) [10]. We included all patients with respect-
ive medication for ≥6 months, at least two consultations
within one year from May 2009 to February 2013 and re-
corded BP measurements. Subsequently, we selected pa-
tients with VKA treatment (ATC coding) for ≥3 months
and compared them to patients without such treatment
regarding BP control. In Switzerland, INR monitoring is
mainly done by GPs using a point-of-care device in
order to review the prescription and adjust dosing of
VKA during the same consultation. We controlled for
potential confounders by performing a linear regression
analysis adjusting for age, sex, observation period, num-
ber of consultations, chronic conditions, coronary heart
disease, heart failure, atherosclerosis, obesity, and dia-
betes. Chronic conditions were defined by applying a set
of specific ICPC-2 codes first described by O’Halloran
et al. [11] and validated for the FIRE database [12].
Moreover, we identified patients with diabetes type two
by prescribed medication (PCG).
Data were analysed using STATA release 13.1 StataCorp,
College Station, TX.
According to current Swiss law on human research
(Humanforschungsgesetz, HFG) retrospective cross-
sectional analysis of anonymized medical routine data
requires no approval by the regional ethics committee
Zürich [13]. Patient records/informations were anon-
ymized and de-identified prior to analysis.
Results
Consultation data of 56,765 adult primary care patients
with at least two consultations within one year between
May 2009 and February 2013 were eligible (Flowchart in
Fig. 1). 6,347 of these patients (11.2 %) had a diagnosis
of hypertension according to their list of medication.
5,026 (79.2 %) had prescribed medication for hyperten-
sion ≥6 months. Out of the 5,026 patients, 4,432
(88.2 %) had records of BP measurements and included
in our study. Among these 4,432, 569 (12.9 %) where
treated with Phenprocoumon ≥3 months and were in-
cluded in the VKA group; 3,843 (87.1 %) patients had no
anticoagulant treatment and were used as controls.
Table 1 depicts the baseline characteristics of patients
in the VKA and control groups. The two groups differed
significantly in age, sex, number of consultations per
year and number and type of chronic conditions. Pa-
tients on VKA were approximately nine years older,
more likely to be female, had more chronic comorbidi-
ties and visited their GP almost twice as often as
controls.
Regarding BP control, both mean systolic and diastolic
blood pressure were significantly lower by 9.2 mm Hg
(systolic) and 4.7 mm Hg (diastolic) in the VKA group
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(p < 0.01 for both) (Table 1). Additionally, the proportion
of patients with controlled BP within target range, de-
fined as <140/90 mm Hg, was significantly higher in the
VKA group (74.9 % vs. 49.5 %, p < 0.01.).
Table 2 provides the mean differences of systolic and
diastolic BP between groups after adjustment for age,
sex, observation period, number of consultations, num-
ber of chronic conditions, coronary heart disease, heart
failure, atherosclerosis, obesity, and diabetes. Again, both
systolic and diastolic BP were significantly lower in the
VKA group, and patients in the VKA group were more
likely to meet the BP target range of <140/90 mm Hg,
odds ratio 2.7 (95 % CI 2.2 – 3.4).
Differences were also observed between the subgroups
of patients with comorbid diabetes (n = 644) (Table 3).
Mean systolic BP was significantly lower in the VKA
group (−7.2 mm Hg, p < 0.001); mean diastolic BP was not
significantly lower (−0.4 mm Hg, p < 0.7). Odds ratio for
controlled BP <140/90 mm Hg was 1.7 (95 % CI 1.0 – 2.8,
p = 0.044).
Fig. 1 Patient flow chart
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Discussion
The aim of the study was to evaluate the effect of INR
monitoring on BP control in primary care patients with
hypertension. The results suggest that the hypothesized
effect exists and that it is clinically relevant. After adjust-
ment for confounders, both systolic and diastolic BP
were significantly lower in the VKA group by about
9 mm Hg and 2 mm Hg, respectively.
These findings lead to the question, ‘Which factor as-
sociated with INR monitoring could cause the effect?’
One explanation is that INR monitoring requires regular
consultations with the GP, where INR values are avail-
able right within the same consultation due to a point-
of-care device. Indeed, comparison showed that patients
under VKA treatment had significantly more consulta-
tions per year with their GP than controls. However, in
the multivariate analysis, we controlled for the number of
consultations and the effect sustained. Similarly, we con-
trolled for the number of chronic conditions, because one
could argue that patients under VKA treatment are more
like to suffer from multiple chronic conditions which re-
quire regular monitoring and increase GPs’ awareness for
BP control. A very common chronic disease that could un-
fold such a confounding effect is diabetes. In fact, the
prevalence of patients with diabetes was approximately
15 % in our study population and therefore in the ex-
pected range considering age and morbidity [14]. More-
over, previous studies have shown that the majority of
patients with diabetes in Swiss primary care undergo regu-
lar BP measurement [15]. Apparently, GPs are aware of
the necessity of BP control in patients with diabetes. So,
we analyzed patients with comorbid diabetes separately.
Again, a lower BP under VKA treatment was observed.
Another explanation is that VKA agents have an in-
herent BP lowering effect. For instance, animal experi-
ments revealed that specific coumarin agents or
compounds have a dose-dependent, BP lowering effect
[16, 17]. However, Phenprocoumon is not among these.
Moreover, if Phenprocoumon had a physical effect on
BP, normotensive patients under VKA treatment would
regularly suffer from hypotension. To conclude, we con-
sider this explanation as rather implausible.
Another explanation for our findings is that INR moni-
toring promotes patients’ adherence to medical therapy
Table 1 Baseline characteristics and blood pressure (BP) of 4,412 patients with hypertension with and without VKA Treatment
VKA group n = 569 Control group n = 3,843 p-value**
Age, years (SD) 76.7 (10.0) 67.8 (13.8) <0.01
Men, % 47.6 52.4 0.044
Consultations/year, n (SD) 10.9 (7.2) 6.6 (5.5) <0.01
Chronic conditions, n (SD) 3.8 (2.5) 3.1 (2.3) <0.01
Coronary heart disease, n (%) 45 (7.9) 224 (5.8) 0.053
Heart failure, n (%) 28 (4.9) 50 (1.3) <0.01
Atherosclerosis, n (%) 28 (4.9) 80 (2.1) <0.01
Obesity, n (%) 20 (3.5) 235 (6.1) 0.01
Diabetes, n (%) 87 (15.3) 557 (14.5) 0.62
Mean systolic BP, mm Hg (SD) 130.6 (14.9) 139.8 (15.8) <0.01
Mean diastolic BP, mm Hg (SD) 76.6 (7.9) 81.3 (9.3) <0.01
Patients with controlled* BP, % 74.9 49.4 <0.01
*defined as blood pressure <140/90 mmHg
**p-value: Results of univariate comparisons between groups based on unpaired t-test or Chi-square test as appropriate
Table 2 Adjusted difference in blood pressure of patients with hypertension with and without VKA Treatment
Patients included (n = 4,412) VKA group vs. control group
Adjusteda mean difference (95 % CI) p-value
Systolic BP (mm Hg) −8.4 (−9.8 − −7.0) <0.01
Diastolic BP (mm Hg) −1.5 (−2.3 − −0.7) <0.01
Adjusted* Odds Ratio (95 % CI) p-value
Controlled BP (<140/90 mm Hg) 2.7 (2.2 – 3.4) <0.001
aadjusted for age, sex, observation period, number of consultations and number of chronic conditions, coronary heart disease, heart failure, atherosclerosis,
obesity, diabetes
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and subsequently enhances the intake of antihypertensive
medication more than other monitoring measures. If so, it
would be interesting to investigate whether the effect
could also be observed in patients who routinely receive
INR measurement by different healthcare providers or
who perform self-monitoring at home.
Our study has several limitations. Due to the design of
our study, we can only speculate about causality between
VKA treatment and better blood pressure control. We
also did not measure compliance to VKA treatment dir-
ectly because our dataset did not contain INR-values or
time in therapeutic range. However, also after adjusting
for several possible confounding factors, we still ob-
served a strong association between VKA and lower
blood pressure. However, there remains the possibility of
residual confounding due to missing data on e.g. BMI
and limitations due to undercoding for reasons for
anticoagulation.
A major strength of our study is that it is based on the
substantial FIRE database and consequently a large sam-
ple size. As in February 2013, the database contained re-
cords from 56,756 patients and led to the inclusion of
4,412 patients in this study. Moreover, our inclusion cri-
teria were rather strict, defining hypertension as antihy-
pertensive medication intake for at least six months. As
newly induced treatments can cause great variations in
blood pressure control, we ensured that patients at the
beginning of antihypertensive treatment were excluded.
Patients who had received VKA treatment for less than
three months were also excluded, in order to avoid the
inclusion of patients under short-term anticoagulation
therapy after thrombosis. Therefore, data can be consid-
ered as representative.
A significant association between VKA treatment and
BP control could be shown. Although, our study method
is limited to a cross-sectional design and not qualified to
prove causality, our findings are of special relevance for
daily practice in primary care. In the light of an increas-
ingly older and multimorbid population, new models of
care are required that are tailored to the needs of chron-
ically ill patients. Indeed, health services research has
yielded several promising concepts, e.g. the Chronic
Care Model or the Patient-Centered Medical Home
Model [18, 19]. However, the implementation of these
concepts into primary care routine of European countries
is challenging and still in the early stage of its develop-
ment [20]. Meanwhile, regularly recurring processes of
care such as INR monitoring in GP practices fill in the
gap and constitute an important opportunity for GPs to
structure care provision, evolve a stable physician-patient-
relationship and provide comprehensive medical care.
Our findings show the importance of this «gap filling»
and highlight that VKA should not be simply replaced by
NOACs without a thorough implementation of new care
models.
Further research is needed, in order to clarify which
aspect of INR monitoring is causative for the observed
BP lowering effect and how it could be systematically
exploited, particularly in multimorbid patients.
Conclusions
In a large sample of hypertensive patients in Switzerland,
Vitamin-K antagonist treatment was associated with bet-
ter systolic and diastolic BP control even after adjusting
for several covariates such as comorbidities and number
of consultations. The observed effect could be due to
better compliance with antihypertensive medication in
patients treated with VKA. Therefore, we conclude to be
aware of this possible benefit especially in patients with
lower expected compliance and with multimorbidity.
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Table 3 Adjusted difference in blood pressure of patients with hypertension and comorbid diabetes with and without VKA Treatment
Subgroup of patients with prescribed diabetes medication (n = 644) VKA group vs. control group
Adjusteda mean difference (95 % CI) p-value
Systolic BP (mm Hg) −7.2 (−10.9 − −3.6) <0.001
Diastolic BP (mm Hg) −0.4 (−2.3 − 1.5) 0.68
Adjusteda Odds Ratio (95 % CI) p-value
Controlled BP (<140/90 mm Hg) 1.7 (1.01 – 2.8) 0.044
aadjusted for age, sex, observation period, number of consultations, number of chronic conditions, coronary heart disease, heart failure, atherosclerosis,
obesity, diabetes
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